Role for Brm in cell growth control

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5069-5076

  Coisy Quivy, Marjorie ^a   Disson, Olivier ^a   Roure, Virginie ^a   Muchardt, Christian ^b   Blanchard, Jean Marie ^a   Dantonel, Jean Christophe ^a  

^a CNRS   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLIN G1; MYC PROTEIN; PROTEIN BRM; PROTEIN P27; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CHROMOSOME SEGREGATION; ENZYME ACTIVITY; ENZYME KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; CELL CYCLE; CELL DIVISION; CELL GROWTH PROCESSES; CHROMOSOME SEGREGATION; FIBROBLASTS; G2 PHASE; GENE EXPRESSION REGULATION; MICE; MITOSIS; TRANSCRIPTION FACTORS;

EID: 33744907493     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0596     Document Type: Article

References (33)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003;114:431-43.
3. Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev 2002;12:73-9.
4. Martens JA, Winston F. Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev 2003;13:136-42.
5. Wang W, Cote J, Xue Y, et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 1996;15:5370-82.
6. Bultman S, Gebuhr T, Yee D, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 2000; 6:1287-95.
7. Reyes JC, Barra J, Muchardt C, et al. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 1998;17:6979-91.
8. Decristofaro MF, Betz BL, Rorie CJ, et al. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 2001;186:136-45.
9. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000;60:6171-7.
10. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-6.
11. Reisman DN, Strobeck MW, Betz BL, et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002;21:1196-207.
12. Muchardt C, Yaniv M. When the SWI/SNF complex remodels...the cell cycle. Oncogene 2001;20:3067-75.
13. Dunaief JL, Strober BE, Guha S, et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994;79: 119-30.
14. Strober BE, Dunaief JL, Guha, Goff SP. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol 1996;16:1576-83.
15. Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T. RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci U S A 1997;94:11268-73.
16. Kadam S, Emerson BM. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 2003;11:377-89.
17. Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC. Linking the Rb and polycomb pathways. Mol Cell 2001;8: 557-69.
18. Coisy M, Roure V, Ribot M, et al. Cyclin A repression in quiescent cells is associated with chromatin remodeling of its promoter and requires Brahma/SNF2alpha. Mol Cell 2004;15:43-56.
19. Muchardt C, Yaniv M. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J 1993;12:4279-90.
20. Boulon S, Dantonel JC, Binet V, et al. Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a pbospho-CREB- and CREB binding protein-independent mechanism. Mol Cell Biol 2002; 22:7769-79.
21. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999;18:2988-96.
22. Woo MS, Sanchez I, Dynlacht BD. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol Cell Biol 1997;17:3566-79.
23. Vries RG, Bezrookove V, Zuijderduijn LM, et al. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 2005;19: 665-70.
24. Tin Su T. Cell cycle: how, when and why cells get rid of cyclin A. Curr Biol 2001;11:R467-9.
25. Secombe J, Pierce SB, Eisenman RN. Myc: a weapon of mass destruction. Cell 2004;117:153-6.
26. Reis T, Edgar BA. Negative regulation of dE2F1 by cyclin-dependent kinases controls cell cycle timing. Cell 2004;117:253-64.
27. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000;14:804-16.
28. Rayman JB, Takahashi Y, Indjeian VB, et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 2002;16:933-47.
29. Claudio PP, Howard CM, Baldi A, et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994;54:5556-60.
30. Fajas L, Le Cam L, Polanowska J, et al. A CDE/CHR-like element mediates repression of transcription of the mouse RB2 (p130) gene. FEBS Lett 2000;471:29-33.
31. Hill DA, Chiose S, Jamaluddin S, et al. Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. J Cell Sci 2004;117:5847-54.
32. Artandi SE, Chang S, Lee SL, et al. Telomere dysftmction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406: 641-5.
33. Isakoff MS, Sansam CG, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A 2005;102: 17745-50.